A new €9.4m consortium named DRIVE-AB has been funded by the EU Innovative Medicines Initiative (IMI) to tackle the growing global threat of antibiotic resistance.
As a public-private partnership, DRIVE-AB (Driving Reinvestment in R&D and Responsible Antibiotic Use) has been set up to develop, test and recommend new economic models for pharmaceutical industry investment over the next 3 years, so they can produce new, effective antibiotics to replace the rapidly diminishing reserve currently available.
Simultaneously, the consortium is also at the helm of examining how the efficacy of existing and new drugs can be maintained and preserved by defining their responsible and appropriate use.
According to the group, around 25,000 people die each year in Europe from multidrug resistance infections and the World Health Organization has identified antimicrobial resistance as one of the three greatest threats to human health, with an estimated annual societal cost of €1.5bn.
Project leader of DRIVE-AB, Stephan Harbarth, University of Geneva said “I am very excited about the ambitious DRIVE-AB agenda that will be delivered by uniting a unique panel of experts across a range of disciplines including medical, scientific, business and economic sciences across clinical, academic and commercial sectors.
“The dual crisis of antibiotic resistance and the near empty antibiotic pipeline pose a very real threat to human health. Only collaboration on this scale, involving stakeholders worldwide will be sufficient to address the crisis. I am confident the worldwide renowned expertise, motivation and diversity of the DRIVE-AB partners are an appropriate match for the complexity and scope of the problem to be confronted.”
For a full list of project partners and more in-depth information about the responsibilities of DRIVE-AB, you can read the full press release.